The mental disorder include various different types of mental disorders such as depression, bipolar disorder, schizophrenia, dementia, post traumatic disorders, and others. These mental disorders are treated with the help of medications or psycho-therapies. Moreover, various medications used for the treatment of these mental disorders include anti-depressants, anti-anxiety medications, anti-psychotic medications, and mood stabilizing medication.
Key companies are focusing on product launches for the treatment of mental disorders such as depression, bipolar disorders to strengthen their position in the global mental disorder treatment market. For instance, in 2017, Lupin Limited, launched its anti-depressant, Bupropion Hydrochloride extended release tablets, indicated for the treatment of major depressive disorder, in the U.S. market.
- This report studies the current scenario as well as the future potential of the global mental disorder treatment market. The market for is segmented on basis of disorder type, medication, distribution channel, and region.
- This report provides in-depth analysis of the global mental disorder treatment market, and provides market size (US$ Bn) and compound annual growth rate (CAGR) (%) for the forecast period (2020-2027)
- It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market. It provides valuable insights about market drivers, restraints, opportunities, country outlook, and competitive strategies adopted by leading players.
- It profiles leading players in the global mental disorder treatment market based on the following parameters – company overview, financial performance, product portfolio, geographical presence, key developments, and future plans.
- Insights from this report would allow marketers and management authorities of companies to make informed decisions with respect to future market expansion and marketing tactics
- The global mental disorder treatment market report caters to various stakeholders in this industry, including investors, product developers and manufacturers, distributors, healthcare organizations, research institutes, new entrants, and financial analysts
- Stakeholders would greatly benefit in decision making through various strategy matrices used in analyzing the global mental disorder treatment market
-
- Depression
- Bipolar Disorder
- Schizophrenia
- Dementia
- Post-traumatic stress disorder
- Others
-
-
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
-
- North America
- Latin America
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
- Germany
- U.K.
- France
- Italy
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC
- Israel
- Rest of Middle East
- Africa
- South Africa
- Central Africa
- North Africa
-
- Allergan plc
- Eli Lilly and Company
- VistaGen Therapeutics
- Sanofi S.A
- Novartis International AG
- Mylan N.V.
- Amneal Pharmaceuticals LLC
- Cipla Ltd
- Sun Pharmaceutical Industries Ltd.
- Glenmark Pharmaceuticals Limited
- Lupin Limited
- Janssen Pharmaceutica
- Bristol Myers Squibb
- Sumitomo Dainippon Pharma Co., Ltd.
